No annual revenue total was found in Definium Therapeutics, Inc.'s SEC filings.
Definium Therapeutics, Inc. (DFTX) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. As of Jun 30, 2026 it held $1.1 billion in cash and investments and $36.5 million in total debt.
Revenue
—
Net income (TTM)
$-353.79M
-208.9% vs year-ago TTM
Operating cash flow (TTM)
$-167.95M
-65.4% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-3.52
-158.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
99.70M
+32.3% vs prior year
Net cash
$1.05B
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- DFTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1813814
- Former names
- Mind Medicine (MindMed) Inc. (until Jan 12, 2026)
Other Medicinal Chemicals & Botanical Products companies
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$166.3M | -$103.9M | -$93.9M | -$66.3M | -$93.9M |
| Net income | -$183.8M | -$108.7M | -$95.7M | -$56.8M | -$93.0M |
| Diluted EPS | -$2.06 | -$1.54 | -$2.44 | -$1.84 | — |
| Operating cash flow | -$131.6M | -$79.1M | -$64.4M | -$50.1M | -$45.8M |
| Total assets | $440.1M | $302.2M | $124.5M | $170.0M | $164.0M |
| Total liabilities | $107.8M | $60.7M | $46.4M | $19.1M | $12.3M |
| Stockholders' equity | $332.3M | $241.4M | $78.1M | $150.9M | $151.7M |
| Cash and investments | $411.6M | $273.7M | $99.7M | $142.1M | $133.5M |
| Total debt | $40.6M | $21.9M | $14.1M | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jun 24, 2026 | Jun 22, 2026 |
All 503 Definium Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.